US FDA clears ZELTIQ's fat-removal treatment for upper arms

Workflow Solutions
Products
See more S&P Global Solutions
See More IHS Markit Solutions
Content
How We Can Help
See More
News & Insights Topics
See More
Featured Events
Webinar ReplaysNew Corporate Realities: Blending Geopolitics, Data, and Digital Transformation
- 07/21/2022
- On-Demand
- 1 Hour
In PersonInteract 2022
- 09/15/2022
- 225 Liberty Street, New York, New York
- 225 Liberty Street
In Person451Nexus
- 10/03/2022
- ARIA Resort and Casino, Las Vegas, Nevada
Platforms
Other Products
- Leveraged Commentary and Data
- Research Online

In This List

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations

26 Jan, 2017 | 15:18

Author Mirza Salam Ahmed
Theme Healthcare & Pharmaceuticals

The U.S. FDA cleared ZELTIQ Aesthetics Inc.'s CoolSculpting, a noninvasive fat-removal technology for upper arms.

The company will also launch the CoolAdvantage Petite applicator for the CoolSculpting system to optimize the performance of CoolSculpting in the upper arms, with full commercial release targeted for the middle of 2017.